<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02227290</url>
  </required_header>
  <id_info>
    <org_study_id>MUS90200_4024_1</org_study_id>
    <nct_id>NCT02227290</nct_id>
  </id_info>
  <brief_title>Pediatric Subjects With Tinea Corporis</brief_title>
  <official_title>A Phase 4, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being done to see how well the study cream works when applied once a day to
      affected area of child (where they have ringworm). The results will be compared to those seen
      with a placebo cream which has no active ingredient. Safety of the cream will also be
      measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to evaluate the safety and efficacy of Naftin (naftifine
      hydrochloride) Cream, 2% applied once daily for 2 weeks, compared to its vehicle in the
      treatment of pediatric subjects aged 2 to 17 years and 11 months with positive potassium
      hydroxide (KOH), positive dermatophyte culture, and clinical signs and symptoms of tinea
      corporis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy</measure>
    <time_frame>Day 21</time_frame>
    <description>Complete cure defined by negative KOH result and negative dermatophyte culture</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy</measure>
    <time_frame>Day 21</time_frame>
    <description>Treatment Effectiveness defined as negative KOH, negative culture, and improved sign and symptoms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical Success at Days 14 and 21</measure>
    <time_frame>Day 14 and Day 21</time_frame>
    <description>Defined as sign and symptom scores of 0 or 1</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical cure at Days 14 and 21</measure>
    <time_frame>Days 14 and 21</time_frame>
    <description>Defined as erythema, induration, and pruritus score of 0.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject Satisfaction</measure>
    <time_frame>Days 14 and 21</time_frame>
    <description>Assessment on 5 point scale or category of improvement from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Complete Cure</measure>
    <time_frame>Day 14</time_frame>
    <description>Defined as negative mycology and abscence of signs/symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment of Effectiveness</measure>
    <time_frame>Day 14</time_frame>
    <description>Defined as negative KOH, negative culture, and signs/symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mycology Cure</measure>
    <time_frame>Day 14</time_frame>
    <description>Defined as negative KOH result and negative dermatophyte culture.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Tinea Corporis</condition>
  <arm_group>
    <arm_group_label>Naftin Cream, 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once Daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftin Cream</intervention_name>
    <arm_group_label>Naftin Cream, 2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Cream</intervention_name>
    <arm_group_label>Placebo Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or non-pregnant females 2 years of age to 17 years, 11 months, of any race.
             Females of child bearing potential must have a negative urine pregnancy test.

          -  Presence of tinea corporis by clinical evidence of a tinea infection of at least
             moderate erythema, moderate induration, and mild pruritus.

          -  KOH positive and culture positive baseline skin scrapings obtained form the site with
             the mose severely affected lesion or a representative site of the overall severity.

        Exclusion Criteria:

          -  Tinea infection of the face, scalp, groin, and/or feet

          -  A life-threatening condition in the opinion of the investigator (ex. autoimmune
             deficiency syndrome, cancer, etc) within the last 6 months.

          -  Subjects with abnormal findings- physical or laboratory- that are considered by the
             investigator to be clinically important and indicative of conditions that might
             complicate interpretation of study results

          -  Subjects with a known hypersensitivity or other contradictions to study medications or
             their components.

          -  Subjects who have a recent history or who are currently known to abuse alcohol or
             drugs.

          -  Uncontrolled diabetes mellitus.

          -  Hemodialysis or chronic ambulatory peritoneal dialysis therapy.

          -  Current diagnosis of immunocompromising conditions.

          -  Current evidence of compromised skin, atopic or contact dermatitis, eczema, impetigo,
             lichen planus, pityriasis rosea, pityriasis versicolor, psoriasis, seborrhoeic
             dermatitis and syphilis.

          -  Severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection

          -  Patients with tinea corporis who have concurrent dermatophytosis of the scalp, beard
             or nails.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Fleischer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merz North America, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Merz Investigative Site#001316</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site# 0010320</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#001313</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#001301</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#001312</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#001311</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site #001310</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#001307</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#001309</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#001314</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#001126</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#001293</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site# 0010319</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#001097</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#180002</name>
      <address>
        <city>San Cristobal</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site# 180001</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#504001</name>
      <address>
        <city>San Pedro Sula</city>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#507001</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#001279</name>
      <address>
        <city>Cidra</city>
        <zip>00739</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Honduras</country>
    <country>Panama</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2014</study_first_submitted>
  <study_first_submitted_qc>August 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2014</study_first_posted>
  <disposition_first_submitted>October 6, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>October 6, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 7, 2016</disposition_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinea Corporis</keyword>
  <keyword>Ringworm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naftifine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

